Trial Profile
Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Brentuximab vedotin (Primary) ; Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms CheckMate 744
- Sponsors Bristol-Myers Squibb
- 09 Apr 2024 Planned primary completion date changed from 8 Jan 2024 to 25 Jun 2024.
- 25 Aug 2023 Planned End Date changed from 6 Jan 2024 to 10 Nov 2024.
- 25 Aug 2023 Planned primary completion date changed from 6 Jan 2024 to 8 Jan 2024.